

HEMOSTATIC PARAMETERS IN PHYSIOLOGICAL AND REACTIVE STATES

Essay

Submitted for Partial Fulfillment of Master Degree in

CLINICAL AND CHEMICAL PATHOLOGY


By

Doaa Abd El-Hamid Hassan
(M.B., B.Ch.)



60019

616.07561
D.A.



Supervised by

Prof. Dr. Zeinab Mohamed Tawfik
Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University

Zeinab Tawfik

Dr. Salwa Mohamed Abu El-Hana
Assistant Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University

Salwa
Ab El-Hana

Dr. Hoda Mohamed El-Gendi
Lecturer of Clinical Pathology
Faculty of Medicine - Ain Shams University

Hoda El-Gendi

Faculty of Medicine
Ain Shams University
1995


Hoda El-Gendi

1995

Doaa Abd El-Hamid Hassan

Doaa Abd El-Hamid Hassan





To

MY FAMILY

ACKNOWLEDGEMENT

I wish to express my deepest thanks and gratitude to ***Professor Dr. Zeinab Mohamed Tawfik, Professor of Clinical Pathology, Ain Shams University***, for her continuous guidance, help, encouragement and generous advice throughout the work.

I would like also to appreciate the help afforded by ***Dr. Salwa Mohamed Abou El Hana, Assistant Professor of Clinical Pathology, Ain Shams University***.

Also, I am very grateful to ***Dr. Hoda Mohamed El Gendy, Lecturer of Clinical Pathology, Ain Shams University***, for her close supervision and help.

LIST OF ABBREVIATIONS

ADP	Adenosine diphosphate.
AMP	Adenosine monophosphate.
α_2 -AP	α_2 -antiplasmin.
APTT	Activated partial thromboplastin time.
ATIII	Antithrombin III.
ATP	Adenosine triphosphate.
C4b	Complement 4b.
CE	Conjugated estrogens.
CVD	Cardiovascular disease.
DB	Dense bodies.
DDAVP	Desamino-8-D-arginine vasopressin.
DIC	Disseminated intravascular coagulation.
DVT	Deep venous thrombosis.
E%	Of total energy.
E ₂	Transdermally administrated estradiol.
EDRF	Endothelium-derived relaxing factor.
ERT	Estrogen replacement therapy.
FDPs	Fibrin degradation products.
FPA	Fibrinopeptide A.
GMP	Guanosine monophosphate.
GP	Glycoprotein.
HMWK	High-molecular weight kininogen.
HRT	Hormone replacement therapy.
IP ₃	Inositol-trisphosphate.
ITP	Immune thrombocytopenic purpura.
MBL	Menstrual blood loss.
MW	Molecular weight.

OC	Oral Contraceptives.
PAI	Plasminogen activator inhibitor.
PC	Protein C.
PCP	Protein C activation peptide.
PF3	Platelet factor 3.
PF4	Platelet factor 4.
PG	Prostaglandin.
PIP ₂	Phosphatidylinositol bisphosphate.
PIVKA	Proteins induced by vitamin K absence.
PT	Prothrombin time.
SLE	Systemic lupus erythematosus.
TAT	Thrombin-antithrombin complex.
t-PAag	Tissue plasminogen activator antigen.
Tx-A ₂	Thromboxane A ₂ .
Tx-B ₂	Thromboxane B ₂ .
Tx-M	Thromboxane metabolites.
u-PA	Urokinase plasminogen activator.
vWF	von Willebrand factor.

LIST OF CONTENTS

	<u>Page</u>
- ABSTRACT.....	1
- INTRODUCTION AND AIM OF THE WORK.....	2
- REVIEW OF LITERATURE	4
* Normal hemostatic mechanisms	4
- Role of endothelium in hemostasis.....	6
- Role of platelets in hemostasis.....	12
- Role of blood coagulation in hemostasis	23
- Mechanism of blood coagulation	25
- Naturally occurring inhibitors of blood coagulation.....	36
- Fibrinolysis.....	41
* Hemostatic parameters in physiological states.....	46
- Effect of age on hemostasis	46
- Hemostasis in the newborn	46
- Hemostatic parameters in different age groups with influence of sex.....	53
- Physiological conditions that affect hemostasis in females.....	61
- Normal menstruation	61
- Normal pregnancy	64
- Effect of diet on hemostasis	71
- Effect of obesity on hemostasis	76
- Effect of physical activity and bed rest on hemostasis.....	77
* Hemostatic parameters in reactive states	81
- Effect of smoking on hemostasis	81
- Effect of oral contraceptives and estrogen replacement therapy on hemostasis	90
- Effect of drugs on hemostasis	96
- Effect of the common antithrombotic agents.....	96
- Effect of chemotherapy.....	106
- Effect of surgery on hemostasis	108
- SUMMARY AND CONCLUSION	110
- REFERENCES.....	115
- ARABIC SUMMARY.....	115

ABSTRACT

